TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ridge Preservation Comparing Simultaneous vs. Delayed Grafting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have one non-molar maxillary tooth requiring extraction that will be replaced by a dental implant. The site must be bordered by 2 teeth.~* Healthy persons at least 18 years old.~* Patients must sign an informed consent approved by the University of Louisville Human Studies Committee.~Exclusion Criteria:~* Patients with debilitating systemic disease, or diseases that have a clinically significant effect on the periodontium.~* Exclude any molar tooth.~* Presence of or history of osteonecrosis of jaws.~* Patients with current or previous history of IV bisphosphonates, irrespective of duration.~* Patients taking oral bisphosphonates for ≥ 3 years.~* Pregnant women.~* Allergy to any material or medication used in the study.~* Patients who need prophylactic antibiotics prior to dental procedures.~* Previous head and neck radiation therapy.~* Chemotherapy in the previous 12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Delayed Grafting (Type: EXPERIMENTAL): 8 weeks after extraction implant placement and simultaneous osseous grafting.
- Simultaneous Grafting (Type: ACTIVE_COMPARATOR): At the time of extraction the socket will be grafted and implant placed 4 months later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Nasaleze on Nasal Challenge With Allergen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Males and females between 18 and 45 years of age.~2. History of grass and/or ragweed allergic rhinitis.~3. Positive skin test to grass and/or ragweed antigen.~4. Positive response to screening nasal challenge.~Exclusion Criteria:~1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.~2. Pregnant or lactating women.~3. Upper respiratory infection within 14 days of study start.~4. FEV1\<80% of predicted at screening for subjects with history of mild asthma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Nasaleze spray (Type: ACTIVE_COMPARATOR): Nasaleze spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge
- Placebo spray (Type: PLACEBO_COMPARATOR): Placebo spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA :~* Patients with nosocomial and/or healthcare-associated bacteremia with Gram-positive cocci in clusters~* Confirmed to be meticillin-resistant S. aureus using a GeneXpert rapid molecular test~* Aged 18 years or older~* Who have given their written consent when this is possible or someone from his/her family, or if not possible, emergency inclusion~* Who can receive follow-up for the entire duration of the study, i.e. 90 days~EXCLUSION CRITERIA :~* Known allergy to vancomycin or daptomycin~* Women who are pregnant or breast-feeding~* Patients who have received vancomycin treatment for more than 48 hours between the diagnostic blood culture and randomization~* Specific sites of infection: pneumonia, meningitis, brain abscess, osteitis, polymicrobial infection~* Life expectancy considered to be less than 72 hours~* Severe hepatic impairment (Child C)~* Short-term intravascular catheters which cannot be removed immediately~EXCLUSION CRITERIA between D1 and D5 inclusive :~* Specific sites of infection: osteitis diagnosed between D1 and D5 inclusive~* Permanent foreign material infection (endovascular stents, replacement heart valves or joints, pace maker etc.) which cannot be removed within 36 hours of the first dose of the study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vancomycin monotherapy (Type: ACTIVE_COMPARATOR): vancomycin monotherapy: standard therapy
- daptomycin monotherapy (Type: EXPERIMENTAL): daptomycin monotherapy: experimental therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving first renal (e.g., kidney) transplant~* Transplant is from a non-HLA-identical living donor~* Willing to use acceptable forms of contraception~Exclusion Criteria:~* Positive for anti-human globulin (AHG) or T-cell cross-match with the donor~* Receiving multiple-organ transplant~* History of cancer within the 5 years prior to study entry. Patients who have certain nonmelanoma skin cancers are not excluded~* Human immunodeficiency virus (HIV) infected~* Hepatitis B (HBV) or C (HCV) virus infected~* Other active infections~* Active tuberculosis (TB) infection within the 3 years prior to study entry~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Belatacept (Type: EXPERIMENTAL): Immunosuppressive protocol consisting of belatacept, glucocorticoids, antithymocyte globulin (ATG), and sirolimus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Lactoferrin for Prevention of COVID-19 in Health Care Workers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman over 18 and under 60 years old~* Physicians or nurses or nurse assitant who work in areas of care for patients with COVID-19 (emergency, hospitalization, and Intensive Care Unit) in hospitals in Lima, Peru.~* Healthy participants, without COVID-19 suggestive symptoms~* Participant who wants to participate and signs the informed consent.~Exclusion Criteria:~* Participant who had a previous diagnosis of COVID-19.~* Participant positive in the initial screening for IgM or IgG or a positive RT-PCR for SARS-CoV-2.~* Participant with the following comorbidities: hypertension, coronary heart disease, diabetes mellitus, obesity, chronic lung disease, cancer, kidney failure, or other hematological disease.~* Pregnant woman.~* Participant that are part of another clinical trial or are taking any supplement or preventive treatment for COVID-19.~* Participant with known allergy to cow's milk protein.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Bovine Lactoferrin (Type: EXPERIMENTAL): Bovine Lactoferrin plus standard measures of personal protection.
- Maltodextrin (Type: PLACEBO_COMPARATOR): Maltodextrin plus standard measures of personal protection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Urinary Incontinence for at least 3 months prior to Screening as a result of Neurogenic Detrusor Overactivity due to Spinal Cord Injury or Multiple Sclerosis.~* Subjects with Spinal Cord Injury must have a stable neurological injury at T1 level or below which occurred at least 6 months prior to Screening.~* Subjects with Multiple Sclerosis must be clinically stable in the investigator's opinion, with no exacerbation (relapse) of MS for at least 3 months prior to Screening.~* Subjects must have had an inadequate response after at least 4 weeks of oral medications used in the treatment of NDO (e.g. anticholinergics, beta-3 agonists) and/or have intolerable side-effects.~* Routinely performing Clean Intermittent Catheterization (CIC) to ensure adequate bladder emptying.~* An average of at least two episodes per day of Urinary Incontinence recorded on the screening bladder diary.~Key Exclusion Criteria:~* Any current condition (other than NDO) that may impact on bladder function.~* Previous or current, tumour or malignancy affecting the spinal column or spinal cord, or any other unstable cause of SCI.~* Any condition that will prevent cystoscopic treatment administration or CIC usage, e.g. urethral strictures.~* Current indwelling bladder catheter, or removal of indwelling bladder catheter less than 4 weeks prior to Screening.~* BTX-A treatment within 9 months prior to Screening for any urological condition (e.g. detrusor or urethral sphincter treatments).~* Any neuromodulation/electrostimulation usage for urinary symptoms/incontinence within 4 weeks prior to Screening. Any implanted neuromodulation device must be switched off at least 4 weeks prior to Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 600 U Dysport® Group (Type: EXPERIMENTAL): None
- 600 U Dysport® Placebo Group (Type: PLACEBO_COMPARATOR): None
- 800 U Dysport® Group (Type: EXPERIMENTAL): None
- 800 U Dysport® Placebo Group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects who are ≥18 years of age, having completed the 16 weeks of treatment in the qualifying core study GLPG0634-CL-224 and who may benefit from filgotinib long-term treatment according to the investigator's judgment.~* Male and female subjects of childbearing potential who engage in heterosexual intercourse must agree to continue to use highly effective methods of contraception as described in the protocol.~* Able and willing to sign the informed consent form (ICF), as approved by the Independent Ethics Committee (IEC) and agree to the schedule of assessments.~Exclusion Criteria:~* Subjects who are deemed not to be benefitting from the study drug based upon lack of improvement or worsening of their symptoms. Local guidelines for subject treatment need to be followed.~* Persistent abnormal laboratory values associated with the use of the study drug (including and not limited to hematology, liver and renal function values), according to the investigator's clinical judgment.~* Subjects who discontinued the qualifying core study GLPG0634-CL-224 due to safety or tolerability issues.~* Subjects who require immunization with live/live attenuated vaccine.~* Diagnosis of rheumatic autoimmune disease or inflammatory joint disease other than psoriatic arthritis, except for Sjögren's syndrome.~* Subjects with symptoms suggestive of uncontrolled hypertension, congestive heart failure, uncontrolled diabetes, cerebrovascular accident, myocardial infarction, unstable angina, unstable arrhythmia or any other cardiovascular condition since the inclusion to the GLPG0634- CL-224 study.~* Subjects with symptoms suggestive of gastrointestinal tract ulceration and/or active diverticulitis since the inclusion to the GLPG0634-CL-224 study.~* Subjects with symptoms suggestive of possible lymphoproliferative disease including lymphadenopathy or splenomegaly since the inclusion to the GLPG0634-CL-224 study.~* Subjects with symptoms suggestive of malignancy since the inclusion to the GLPG0634-CL-224 study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- filgotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Bispectral Index (BIS) for Monitoring of Total Intravenous Anaesthesia in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) physical status 1 or 2~* General anesthesia for the following operations: Tonsillectomy, Adenoidectomy, Myringoplasty, Myringotomy with tube placement, microlaryngoscopy, bronchoscopy and esophagoscopy.~Exclusion Criteria:~* Psychiatric disorder~* Use of psychotherapeutic, antiepileptic, antiarrhythmic drugs~* Chronic use of opioids~* Intake of more than 21 alcoholic drinks/week~* Missing informed consent

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Patients receive general anesthesia with Propofol and Remifentanil following clinical practice.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters.
- Bispectral Index Monitor (Type: EXPERIMENTAL): Patients receive a general anesthesia with Propofol and Remifentanil where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tamsulosin to Prevent Postoperative Urinary Retention in Laparoscopic Inguinal Hernia Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All patients undergoing elective laparoscopic inguinal hernia repair, unilateral or bilateral.~2. ≥18 years of age.~3. Patients must leave the operating room without at indwelling urinary catheter.~Exclusion Criteria:~1. History of neurogenic bladder requiring routine intermittent catheterization~2. Emergent laparoscopic hernia repair.~3. Elective laparoscopic hernia repair in conjuncture with an additional operation (e.g. nephrectomy, pelvic surgery) that requires the patient to have a planned, indwelling urinary catheter in the postoperative period.~4. Pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients undergoing laparoscopic inguinal hernia repair will randomized to one dose of placebo in the preoperative holding area 2 hours before surgery.
- Interventional (Type: EXPERIMENTAL): Patients undergoing laparoscopic inguinal hernia repair will be randomized to one dose of 0.4 mg tamsulosin in the preoperative holding area 2 hours before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Yoga for the Treatment of Pediatric Headaches

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 13-17 years~* patient seen in the headache clinic at Children's Hospital of Wisconsin~Exclusion Criteria:~* neck, spinal, or back injuries

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 8 weeks of Yoga, followed by 8 weeks of follow-up
- 2 (Type: ACTIVE_COMPARATOR): 8 weeks of follow-up, followed by 8 weeks of yoga

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of an Interdisciplinary Fitness and Social Engagement Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* TBI of at least mild severity using criteria related to disturbance of consciousness~* Most recent TBI occurred \>1 year prior to consent process~* Medically stable with physician approval to participate~Exclusion Criteria:~* Unable to provide informed consent and no proxy available~* Prior history of known bipolar disorder or schizophrenia or severe psychiatric illness~* Veterans with any cardiac condition that may cause sudden decompensation during cardiovascular testing and training (e.g., severe congestive heart failure and uncontrolled hypertension)~* Veteran is currently active in a skilled physical therapy program.~* Veterans who meet or exceed American Heart Association and American College of Sports Medicine guidelines for physical activity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- InFuSE (Type: EXPERIMENTAL): Experimental group which will receive health education, group discussion, and supervised exercise.
- Patient Education/Group Discussion (Type: ACTIVE_COMPARATOR): Active control group which will receive health education and group discussion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Strike With Bortezomib in Multiple Myeloma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with multiple myeloma currently or previously enrolled on UARK 98-026 and currently event-free at the time of the evaluation.~* Performance status of 0-2 based of Southwest Oncology Group (SWOG) criteria~* Previously documented platelet count \> 75,000/ul within a 35 days prior to enrollment~* Previously documented peripheral absolute neutrophil count \>1,000/ul within 35 days prior to enrollment.~* Adequate renal function~* Signed informed consent~* Female subject is post-menopausal or willing to use acceptable birth control~* Male subjects agree to use acceptable method of contraceptive~Exclusion Criteria:~* Hypersensitivity to Bortezomib, boron, or mannitol~* Female subject is pregnant or breastfeeding~* Experienced myocardial infraction within 6 months prior to enrollment~* Received other investigational new drugs within 14 days before enrollment~* Received any anti-myeloma therapy within 14 days~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study~* Diagnosed or treated for another malignancy within 3 years of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bortezomib/Treatment Arm (Type: ACTIVE_COMPARATOR): Bortezomib Maintenance Year 1 - bortezomib days 1, 4, 8, 11 every 28 days Year 2 - bortezomib days 1, 4, 8, 11 every 2 months Year 3 - bortezomib days 1, 4, 8, 11 every 3 months
- Observation Arm (watchful waiting) (Type: NO_INTERVENTION): monitor myeloma parameters every 3-6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Eligible for, randomised and continuing in TRIDENT Main Study~2. No contraindications to MRI scan of the brain~3. Provide informed consent for the MRI Sub-Study~Exclusion Criteria:~1. Any MRI contraindications (e.g. metallic implants, claustrophobia, etc.)~2. Less than 6 weeks or greater than 6 months post-randomisation (however, where possible the baseline MRI Sub-Study scan should be conducted as soon as possible after the qualifying ICH. e.g. if the qualifying ICH was 4 months prior to randomisation, the baseline scan should be done as close to 6 weeks post-randomisation as possible)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triple Pill (Active Treatment) (Type: EXPERIMENTAL): telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
- Placebo (Type: PLACEBO_COMPARATOR): received via blinded study oral capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility